drugset / Trial / NCT03017547
A Phase 2 Study of IC14 in Acute Respiratory Distress Syndrome
RandomizedSingle-groupQuadruple-blindTreatment
Summary
Acute Respiratory Distress Syndrome (ARDS) patients will be randomized to receive either IC14 (a single dose of 4 mg/kg followed by 2 mg/kg on Days 2-4) or placebo. Study participation will be for a total of 28 days.
Timeline
- Start
- 2019-06
- Primary completion
- 2020-06
- Completion
- 2020-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | IC14 | Monoclonal antibody | 2 mg/kg | Intravenous |